These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37030057)

  • 41. Association of 340B contract pharmacy growth with county-level characteristics.
    Nikpay S; Gracia G; Geressu H; Conti R
    Am J Manag Care; 2022 Mar; 28(3):133-136. PubMed ID: 35404549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of critical access hospital conversion on beneficiary liability.
    Gilman BH
    J Rural Health; 2008; 24(4):400-6. PubMed ID: 19007395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Examining the Benefits of the 340b Drug Discount Program.
    Gerlach J; McSweeney S; Swearingen A; Coustasse A
    Health Care Manag (Frederick); 2018; 37(3):225-231. PubMed ID: 29901471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating The Role Of Payment Policy In Driving Vertical Integration In The Oncology Market.
    Alpert A; Hsi H; Jacobson M
    Health Aff (Millwood); 2017 Apr; 36(4):680-688. PubMed ID: 28373334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost consequences of the 340B drug discount program.
    Conti RM; Bach PB
    JAMA; 2013 May; 309(19):1995-6. PubMed ID: 23609758
    [No Abstract]   [Full Text] [Related]  

  • 46. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs.
    Anderson KE; DiStefano MJ; Liu A; Mattingly TJ; Socal MP; Anderson GF
    Value Health; 2023 Sep; 26(9):1381-1388. PubMed ID: 37285915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of 340B Hospitals Receiving Medicare Part B Repayments.
    Nikpay S
    JAMA Health Forum; 2024 Apr; 5(4):e235397. PubMed ID: 38669033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020.
    Dickson S; Gabriel N; Hernandez I
    JAMA Health Forum; 2023 Nov; 4(11):e234091. PubMed ID: 37976048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fast track to 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Jan; 70(1):56-62. PubMed ID: 26863836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
    Shi L; Wharton MK; Monnette A
    Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2015 rates; quality reporting requirements for specific providers; reasonable compensation equivalents for physician services in excluded hospitals and certain teaching hospitals; provider administrative appeals and judicial review; enforcement provisions for organ transplant centers; and electronic health record (EHR) incentive program. Final rule.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2014 Aug; 79(163):49853-50536. PubMed ID: 25167590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2017 Rates; Quality Reporting Requirements for Specific Providers; Graduate Medical Education; Hospital Notification Procedures Applicable to Beneficiaries Receiving Observation Services; Technical Changes Relating to Costs to Organizations and Medicare Cost Reports; Finalization of Interim Final Rules With Comment Period on LTCH PPS Payments for Severe Wounds, Modifications of Limitations on Redesignation by the Medicare Geographic Classification Review Board, and Extensions of Payments to MDHs and Low-Volume Hospitals. Final rule.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2016 Aug; 81(162):56761-7345. PubMed ID: 27544939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
    Dickson SR; Gabriel N; Gellad WF; Hernandez I
    JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 340B Drug Pricing Program Reform.
    Fong WH
    JAMA Oncol; 2016 Mar; 2(3):403. PubMed ID: 26967190
    [No Abstract]   [Full Text] [Related]  

  • 55. Estimated Medicare Part B Savings From Inflationary Rebates.
    Egilman AC; Kesselheim AS; Rome BN
    JAMA; 2023 Jan; 329(1):89-92. PubMed ID: 36594954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 340B Drug Pricing Program Reform-Reply.
    Kantarjian H; Chapman R
    JAMA Oncol; 2016 Mar; 2(3):403-4. PubMed ID: 26967191
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparison of critical access hospitals and other rural acute care hospitals in Pennsylvania.
    Pai DR; Dissanayake CK; Anna AM
    J Rural Health; 2023 Sep; 39(4):719-727. PubMed ID: 36916142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
    Health Resources and Services Administration, Department of Health and Human Services (HHS)
    Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medicare program: hospital outpatient prospective payment system and CY 2011 payment rates; ambulatory surgical center payment system and CY 2011 payment rates; payments to hospitals for graduate medical education costs; physician self-referral rules and related changes to provider agreement regulations; payment for certified registered nurse anesthetist services furnished in rural hospitals and critical access hospitals. Final rule with comment period; final rules; and interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2010 Nov; 75(226):71799-2580. PubMed ID: 21121180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.